Sihuan Pharmaceutical Holdings Group (HKSE:00460) EBIT: HK$680 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00460 Sihuan Pharmaceutical Holdings Group Ltd HKSE:00460
79 GF Score
Price HK$0.93
GF Value HK$1.18
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sihuan Pharmaceutical Holdings Group EBIT?

Sihuan Pharmaceutical Holdings Group HKSE:00460 +3.33% 79 EBIT is HK$680 Mil as of Dec. 2025. GuruFocus rates HKSE:00460 with a GF Score™ of 79/100 and a GF Value™ of HK$1.18 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sihuan Pharmaceutical Holdings Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$394 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$680 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sihuan Pharmaceutical Holdings Group's annualized ROC % for the quarter that ended in Dec. 2025 was 2.98%. Sihuan Pharmaceutical Holdings Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 28.44%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sihuan Pharmaceutical Holdings Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 11.62%.

Sihuan Pharmaceutical Holdings Group  (HKSE:00460) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sihuan Pharmaceutical Holdings Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=487.486 * ( 1 - 54.19% )/( (7336.901 + 7652.578)/ 2 )
=223.3173366/7494.7395
=2.98 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11610.562 - 1551.119 - ( 4037.096 - max(0, 3637.104 - 6359.646+4037.096))
=7336.901

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12850.084 - 1924.553 - ( 4393.809 - max(0, 4076.485 - 7349.438+4393.809))
=7652.578

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Sihuan Pharmaceutical Holdings Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=788.414/( ( (2816.001 + max(-1924.146, 0)) + (2728.155 + max(-1554.497, 0)) )/ 2 )
=788.414/( ( 2816.001 + 2728.155 )/ 2 )
=788.414/2772.078
=28.44 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(667.685 + 516.197 + 305.753) - (1551.119 + 0 + 1862.662)
=-1924.146

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1173.14 + 682.42 + 365.839) - (1924.553 + 0 + 1851.343)
=-1554.497

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sihuan Pharmaceutical Holdings Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=680.473/5854.045
=11.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sihuan Pharmaceutical Holdings Group EBIT Related Terms

Sihuan Pharmaceutical Holdings Group EBIT Historical Data

* Premium members only.

The historical data trend for Sihuan Pharmaceutical Holdings Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sihuan Pharmaceutical Holdings Group EBIT Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 751.04 -2,134.71 118.21 -163.74 683.53

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.30 121.92 -284.65 286.27 394.21

HKSE:00460 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sihuan Pharmaceutical Holdings Group EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's EV-to-EBIT falls into.


HKSE:00460
79GF Score
Sihuan Pharmaceutical Holdings Group Ltd HKSE:00460
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sihuan Pharmaceutical Holdings Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$680 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$680 Mil mean?
Sihuan Pharmaceutical Holdings Group (HKSE:00460) has a EBIT of HK$680 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sihuan Pharmaceutical Holdings Group.
Is Sihuan Pharmaceutical Holdings Group's EBIT too high?
Sihuan Pharmaceutical Holdings Group's current EBIT is HK$680 Mil. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's EBIT compare to ZTS and UTHR?
Sihuan Pharmaceutical Holdings Group's EBIT of HK$680 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sihuan Pharmaceutical Holdings Group. Sihuan Pharmaceutical Holdings Group's current EBIT is HK$680 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (HKSE:00460) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$1.18, compared to a current price of HK$0.93 — trading 21.2% below its estimated fair value. The current EBIT is HK$680 Mil. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (HKSE:00460), the current EBIT is HK$680 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sihuan Pharmaceutical Holdings Group (HKSE:00460) Overvalued in 2026?

Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued. The current stock price of HK$0.93 is trading 21.2% below its estimated GF Value™ of HK$1.18. GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.

Key valuation signals for HKSE:00460:

  • EBIT: HK$680 Mil
  • GF Value™: HK$1.18 vs. price of HK$0.93 (21.2% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the HKSE:00460 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sihuan Pharmaceutical Holdings Group Business Description

Other Exchanges TEL1:Germany
Address 1 Harbour Road, Convention Plaza, Room 4905, Office Tower, Wanchai, HKG
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
79GF Score

Get the complete analysis for HKSE:00460

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.93
Price
HK$1.18
GF Value